One such development involves multilayered, surface amino-modified single-band up-conversion nanoparticles (sb-UCNPs) conjugated with antibodies specific to breast cancer biomarkers like progesterone receptor (PR), estrogen receptor (ER), and human epidermal growth factor receptor 2 (HER2). This evidence concerns the gene ERBB2 and breast carcinoma.